Founded in 1968, CR&T is committed to funding research that seeks new treatments and cures for cancer, with a particular focus on blood cancers, especially the myeloproliferative neoplasms (MPNs). The cornerstone of our research strategy is a multi-million-dollar commitment to the Richard T. Silver MPN Center at Weill Cornell Medicine in New York City. CR&T also supports patient education, hosting a biennial International Patient Symposium on Myeloproliferative Neoplasms.
Founded in 1968, CR&T is committed to funding research that seeks new treatments and cures for cancer, with a particular focus on blood cancers, especially the myeloproliferative neoplasms (MPNs). The cornerstone of our research strategy is a multi-million-dollar commitment to the Richard T. Silver MPN Center at Weill Cornell Medicine in New York City. CR&T also supports patient education, hosting a biennial International Patient Symposium on Myeloproliferative Neoplasms.